medigraphic.com
Órgano Oficial de el Colegio Mexicano de Urología

2007, Number 3

<< Back Next >>

Bol Col Mex Urol 2007; 22 (3)

Gemcitabina intravesical en el tratamiento del carcinoma urotelial no músculo invasor

López FR, Sánchez VG, González OA, Solano MHA

Language: Spanish
References: 34
Page: 113-119
PDF size: 101.76 Kb.


ABSTRACT

Background: Bladder cancer is the 9th most comon in general population. Transitional cell carcionoma is the most frequent histological subtype. Intravesical 40 mg/mL Gemcitabine instillation has demonstrated to be well tolerated and to reduce tumoral recurrence and progression. Objective: To determine toxicity and efficacy of intravesical Gemcitabine in the treatment of superficial bladder cancer in our population. Methods: Reviewed charts of 21 patients who underwent transurethral bladder tumor resection followed by intravesical Gemcitabine. Results: Treatment protocol consisted in 2,000 mg Gemcitabine diluted in 100 mL, bladder persistence of 120 minutes, 6 weekly cycles followed by 6 monthy applications. It was reported as well tolerated in 85% of the patients. Toxicity was found in 66% of the patients it was mostly low grade and transitory. In respect to tumor control we found 94.7% of patient free of recurrence and progression during a 17.3 ± 12.9 month follow up. Conclusions: The 12 cycle Gemcitabine protocol showed better response when compared to the short 6 cycle protocol without increasing toxicity. Further protocols including larger number of patients and a longer follow up period are needed to reinforce the present results.


REFERENCES

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10-30.

  2. Compendio de Cáncer del RHNM Registro Histológico de Neoplasias Malignas de México 2001.

  3. Secretaría de Salud Jalisco. Boletín del Registro Estatal del Cáncer. Jalisco: 2005, p 25-32.

  4. Dalbagni G, Russo P, Scheinfeld J, Mazumdar M et al: Phase I Trial of Intravesical Calmette-Guerin Refractory Transitional- Cell Carcinoma of the Bladder. J Clin Oncol 2002; 20(15): 3193-8.

  5. Heney NM, Ahmed S, Flanagan MJ: Superficial Bladder Cancer Progresion and Recurrence. J Urol 1983; 130: 1083.

  6. Althausen, et al. Althausen AF, Prout Jr GR, Daly JJ: Noninvasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116: 575-80.

  7. Flamm J, Donas S. The Significance of Bladder Quadrant Biopsies in Patients With Primary Superficial Bladder Cancer. Eur Urol 1989; 16: 81-5.

  8. Menachem L, Sakkaraipan R, Mark P, et al. Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of The Bladder: A Phase I and Pharmacokinetic Study. J Clin Oncol 2003; 21: 697-703.

  9. Gontero P, Luca M, Frea B. Intravesical Gemcitabine for Superficial Bladder Cancer: rationales for a new treatment option. BJU International 2005; 96: 970-6. 10.Thrasher and Crawford, Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am 1992; 19: 529.

  10. 11.Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205-9.

  11. 12.Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: Results of a metaanalysis. Anticancer Res 2001; 21: 765-9.

  12. 13.Ro JY, Staerkel GA, Ayala AG. Cytologic and Histologic Features of Superficial Bladder Cancer. Urol Clin North Am 1992; 19: 435-53.

  13. 14.Ashish M, Lamm DL. Intravesical theraphy for bladder cancer. Urology 2000; 55: 161-8.

  14. 15.Onur O, Queliker R. Polyarthritis as Complication of Intravesical Bacilus Calmette-Guerin Inmunotherapy for Bladder Cancer. Clin Rheumatol 1999; 18(1): 74-5.

  15. 16.De Diego A, Rogado MC, Prieto M. Diseminated Pulmonary Granulomas After Intravesical Bacilus Calmette-Guerin Inmunotherapy. Respiration 1997; 64(4): 304-6.

  16. 17.Matel FM, Giovanelli V, Schepis L. Granulomatous Prostatitis as Collateral Efect of Intravesical Inmunotherapy with BCG. Arch Ital Urol Androl 1998; 70(4): 177-82.

  17. 18.Herr HW, Dabalgani G. Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol 2003; 169: 1706-8.

  18. 19.Punnen SP, Chin JL, Jewett MA. Management of bacilusCalmette-Guérin refractory superficial bladder cancer: results with intravesical BCG ans interferon combination therapy. Can J Urol 2003; 10: 1790-5.

  19. 20.Joudi FN, O’Donnell MA. Second-line intravesicaltherapy versus cystectomy for bacillus Calmette-Guerin failures. Curr Opin Urol 2004; 14: 271-5. 21.Informacióm amplia para prescribir, forma farmaceútica y formulación de Gemzar* (Gemcitabine). CDS 22-JUN -2005. Laboratorios Lilly. 22.Maymi J, Saltsgaver N, O’Donnell MA. New intravesical sequential chemotherapy for patients with treatment refractory superficial urothelial carcinoma. Poster presentation before the Proceedings of the Society of Urologic Oncology. 2004. 23.De Berardinis E, Antonini G, Autran Gomez AM, Codacci Pisanelli G, Di Silverio F, Peters GJ. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. A phase II study with chemoresection of the marker lesion. J Urol 2004; 171: A272. 24.Serreta V, Pavone C, Galuffo A, et al. A pase I-II study on intravesical gemcitabine in superficial bladder papillary tumors. J Urol 2004; 171: A274.

  20. 25.Gontero P, Casetta G, Maso G, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermédiate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46: 339-43.

  21. 26.Laufer M, Ramalingam S, Schoenberg MP et al. Intravesical gemcitabine therapy for superficial transitional cellcarcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21: 697-703.

  22. 27.Rintala E, Jauhiainen K, Alfthan O, Hansson E, Juusela H, Kanerva K, Korhonen H, Permi J, Sotarauta M, Vaalasti T, et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol 1991; 20(1): 19-25.

  23. 28.Massimo M, Campodonico F, Canepa G, et al. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low-or intermédiate-risk, transitional cel carcinoma of the baldder. Eur Uro 2006, doi:10.1016/ j.eururo.2006.08.038

  24. 29.Peyromaure M, Guerin F, Amsellem OD, Saighi D, Debre B, Zerbib M. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cel carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 2003; 169: 2110-2.

  25. 30.Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicenter trial of adjuvant therapy en superficial bladder cancer: transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996; 156: 962-6.

  26. 31.Dalbagni G, Mazumdar M, Russo P, et al. Phase II trial of intravesical gemcitabine in BCGrefractory transitional cellcarcinoma of the bladder. J Urol 2004.

  27. 32.Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995; 45: 387.

  28. 33.Neal D, Sharples L, Smith K. The epidemical grow factor receptor and the prognosis of blader cancer. Cancer 1990; 65: 1619-21.

  29. 34.Lamm DL. Intravesical therapy for superficial bladder cancer: slow but steady progress. J ClinOncol 2003; 21: 4259-60.

  30. 35.Bohle A, Jocham D, Bock PR. Intrvesical Bacilus Calmette- Guerin versus mitomycin C for superficial bladder cancer a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 90-5.

  31. 36.Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette- Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96- 100.

  32. 37.Witjes JA. Bladder carcinoma insitu in 2003. State of the art. Eur Urol 2004; 45: 142-6.

  33. 38.De Berardinis E, Antonini G, Peters GJ, et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 2004; 93: 491-4.

  34. 39.Witjes JA, van der Heljden AG, Vriesema JL, Peters GJ, Laan A. Intravesical gemcitabine a phase I and pharmacokinetic study. Eur Urol 2004; 45: 182-6.




2020     |     www.medigraphic.com